ArticlePloS one2014
Memory decline in Down syndrome and its relationship to iPF2alpha, a urinary marker of oxidative stress.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- Plasma amyloid and tau as dementia biomarkers in Down syndrome: Systematic review and meta-analyses.Developmental neurobiology · 2019Pooled it
- Exploring peripheral fluid biomarkers for early detection of Alzheimer's disease in Down syndrome: A literature review.Heliyon · 2025Review
- Association Between Severe Chronic Obstructive Pulmonary Disease and Polyneuropathy.Medical science monitor : international medical journal of experimental and clinical research · 2021Article
- The Clinical and Neuropathological Features of Sporadic (Late-Onset) and Genetic Forms of Alzheimer's Disease.Journal of clinical medicine · 2021Review
- Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer's disease.Alzheimer's research & therapy · 2019Article
- Increased Oxidative Stress as a Risk Factor in Chronic Idiopathic Axonal Polyneuropathy.Journal of molecular neuroscience : MN · 2018Article
- Neurofilament light as a blood biomarker for neurodegeneration in Down syndrome.Alzheimer's research & therapy · 2018Article
- Alzheimer's disease in Down syndrome: An overlooked population for prevention trials.Alzheimer's & dementia (New York, N. Y.) · 2018Review
- Clinical aspects and biomarkers of Alzheimer's disease in Down syndrome.Free radical biology & medicine · 2018Review
- Cognitive ability in Down syndrome and its relationship to urinary neopterin, a marker of activated cellular immunity.Neuroscience letters · 2017Article
- Developing an Informant Questionnaire for Cognitive Abilities in Down Syndrome: The Cognitive Scale for Down Syndrome (CS-DS).PloS one · 2016Article
- Intracerebral haemorrhage in Down syndrome: protected or predisposed?F1000Research · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundLipid peroxidation may be a marker of free-radical-mediated injury associated with Alzheimer's disease (AD). We aimed to investigate whether changes in lipid peroxidation is associated with cognitive decline in individuals with Down syndrome over a 4-year period.
methodsThirty-two adults with DS participated in a longitudinal study with urinary isoprostane 8,12-iso-iPF2alpha (iPF2alpha) assays at baseline and four years follow-up. Informants rated their functional ability and memory function and the adults with DS attempted assessments of language skills and memory. Twenty-six individuals completed assessments of memory (Modified Memory Object Task, MOMT), adaptive behavior (ABAS), and receptive vocabulary (British Picture vocabulary, BPVS) at both time-points.
resultsOverall change in iPF2alpha level was negatively correlated with change in the MOMT score (Spearman's Rho = -0.576, p = 0.006), i.e., increased lipid peroxidation was correlated with worse memory functioning over time. An increase of ≥ 0.02 ng/mg creatinine iPF2α had good sensitivity (85.7%), positive predictive value (75%,), specificity (85.7%) and negative predictive value (92.3%) for memory decline.
conclusionChange in iPF2alpha over time may have potential as a biomarker for memory decline in Down syndrome and potentially also help to track progression of MCI to AD in the general population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.